

Siena (IT) and San Francisco, CA, USA, 27/03/2019

Exosomics S.p.A., a pioneer and world leader in exosome solutions, today announced the launch of the ExoRef™ line of products, the world first exosome-based reference standards for monitoring the performance of exosome-based liquid biopsy workflows.



Exosomes are small extracellular vesicles present in all human biofluids and contain DNA, RNA and proteins originating from their parent cells. The analysis of exosomes and their content is emerging as a complementary alternative to circulating-free DNA (cfDNA) and Circulating Tumour Cells (CTCs) for patient stratification, monitoring of tumour progression, recurrence and drug resistance.

Now, Exosomics expands its offering with ExoRef™, renewable positive controls designed to monitor the performance of exosome-based diagnostic workflows from sample preparation to the pre-analytical and analytical phases.

ExoRef™ are exosomes in a dry format, characterised for their number, size, purity and genetic content. These highly characterised exosomes can be spiked-in into any biological matrix (blood, plasma, urine, cerebrospinal fluid) to assess the efficiency of exosome isolation procedures and the ability to extract cancer relevant genetic information carried within.

ExoRef™ contain a defined mutation load of mutated EGFR, KRAS or BRAF characterised by droplet digital PCR. Other genes or specific RNAs can be requested as custom products.

Exosomics has already developed and launched on the market the first solutions (SeleCTEV™ and SoRTEV™) for the selective isolation of tumour-derived exosomes and analysis of their genetic content. Antonio Chiesi, CEO of Exosomics said: "Exosomes analysis is rapidly gaining interest from assay developers, pharma and clinicians as a complementary approach to cfDNA and CTCs for non-invasive cancer diagnostics. Reference material is of primary importance to assess the performance of pre-analytical and analytical workflows and to give confidence to the operator that the diagnostic procedure works. We are very proud to lead the exosome-based diagnostic field with such an important material that will ultimately benefit patients through further enabling the adoption of liquid biopsies."

